AstraZeneca Harmonizes Listing Structure

TL;DR

AZN is simplifying its listings, good for Nasdaq investors.

AI Summary

AstraZeneca PLC announced on September 29, 2025, that it is harmonizing its listing structure. This move aims to simplify its corporate structure and enhance its listing on the Nasdaq Stock Market, aligning it with its listing on the London Stock Exchange. The company previously operated under a dual listing structure.

Why It Matters

This harmonization simplifies AstraZeneca's corporate structure, potentially making it easier for investors to track and trade its shares, especially on the Nasdaq.

Risk Assessment

Risk Level: low — The filing is an administrative update regarding listing structure harmonization, not a financial event with immediate material risk.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Nasdaq Stock Market (company) — Exchange
• London Stock Exchange (company) — Exchange
• ZENECA GROUP PLC (company) — Former Company Name

FAQ

From the Filing

0001654954-25-011175.txt : 20250929 0001654954-25-011175.hdr.sgml : 20250929 20250929065917 ACCESSION NUMBER: 0001654954-25-011175 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250929 FILED AS OF DATE: 20250929 DATE AS OF CHANGE: 20250929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251352063 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a1788b.htm AZN HARMONISES LISTING STRUCTURE a1788b FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of September 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________                           AstraZeneca PLC   INDEX TO EXHIBITS     1. AZN harmonises listing structure   29 September 2025   AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange   Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs   AstraZeneca continues to be listed, headquartered and tax resident in the UK   AstraZeneca plans to harmonise its share listing structure to deliver a global listing for global investors in a global company. The Board of AstraZeneca is recommending to shareholders a Harmonised Listing Structure for the Company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange (NYSE).     This requires upgrading AstraZeneca's existing US equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing US listing of AstraZeneca ADRs on Nasdaq. Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the LSE, STO and NYSE.   Michel Demaré, Chair, AstraZeneca said: "Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enablin